MP52-16 ANDROGEN DEPRIVATION THERAPY INCREASED THE RISK OF PULMOMARY EMBOLISM IN PATIENT WITH PROSTATE CANCER - FROM 24,464 PATIENTS, TAIWAN NATIONAL HEALTH INSURANCE RESEARCH DATABASE

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) III1 Apr 2018MP52-16 ANDROGEN DEPRIVATION THERAPY INCREASED THE RISK OF PULMOMARY EMBOLISM IN PATIENT WITH PROSTATE CANCER - FROM 24,464 PATIENTS, TAIWAN NATIONAL HEALTH INSURANCE RESEARCH DATABASE Jian-Hua Hong, Yu-Chuan Lu, Chao-Yuan Huang, and Yeong-Shiau Pu Jian-Hua HongJian-Hua Hong More articles by this author , Yu-Chuan LuYu-Chuan Lu More articles by this author , Chao-Yuan HuangChao-Yuan Huang More articles by this author , and Yeong-Shiau PuYeong-Shiau Pu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1667AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen deprivation therapy (ADT) has been one kind of treatments for prostate cancer (PCa) but subsequent risks of some complications should be considered. Therefore, we aim to investigate the risks of peripheral arterial occlusive disease (PAOD) and pulmonary embolism (PE) in PCa patients with ADT treatment. METHODS We constructed a retrospective cohort study of total 24,464 men with newly diagnosed PCa from a longitudinal health insurance database of catastrophic illness patients in Taiwan. All patients were further divided into one treatment group and two matched control groups: 1) patients undergoing ADT treatment (ADT group), 2) PCa patients without ADT and are individual-matched with age (comparison 1 group), and 3) PCa patients without ADT and are propensity score-matched with continuous age and comorbidity etc. (comparison 2 group). Individual comorbidity history as well as outcome ascertainments of PAOD and PE were obtained from clinical diagnosis and medical records. Multivariate Cox proportional hazard regression and Kaplan–Meier analysis were performed in the present analyze. RESULTS During the 11 year follow-up, the incidence rates of PE were 1.41, 0.93, and 0.63 as well as those of PAOD were 3.60, 4.04 and 3.21per 1000 person-years in the ADT, comparison 1, and comparison 2 groups, respectively. PCa patients with ADT treatment significantly increased nearly twofold risk of PE, especially for those receiving combined androgen blockade or surgical castration. However, no association between ADT therapy and PAOD risk were observed. ADT patients with specific comorbidities, such as other cancers, heart failure or stroke had a much higher risk of subsequent PE. In addition, ADT patients with stroke had a twofold increase in the risk of PAOD. CONCLUSIONS CAB or surgical castration increased subsequent risk of PE, neither for PAOD risk. This treatment should be considered for patients with certain clinical comorbidities. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e701-e702 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jian-Hua Hong More articles by this author Yu-Chuan Lu More articles by this author Chao-Yuan Huang More articles by this author Yeong-Shiau Pu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...